Faron and City of Hope to develop Phase II trial of bexmarilimab for r/r MDS
Faron Pharmaceuticals has collaborated with cancer research organisation City of Hope to develop a Phase II investigator-initiated trial for evaluating …
Post
-
-
FDA releases hold on second of Intellia’s ATTR-CM gene therapy trials
The US Food and Drug Administration (FDA) has released the clinical hold on a second trial evaluating Intellia Therapeutics’ transthyretin …
-
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, …
-
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026
Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing …
-
FDA tells uniQure to conduct another study of Huntington’s gene therapy
uniQure's stock has dropped by more than 40% after being asked to conduct another study of its Huntington’s disease gene …
-
BlueWind’s Revi urinary incontinence device demonstrates three-year efficacy
BlueWind Medical’s Revi implantable tibial neuromodulation (ITNM) system has demonstrated sustained efficacy and safety at the three-year mark in a …
-
MSD announces results from Keytruda combination trial for RCC
Merck (MSD) has announced findings from the pivotal Phase III LITESPARK-022 trial, assessing the combination of Keytruda (pembrolizumab) and Welireg …
-
Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy
Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy for the …
-
OCT West Coast: China’s clinical trial infrastructure delivers upto 60% cost savings
China’s rise as a source of innovative drugs is being driven by clinical trial environment that is proving to be …
-
Rare Disease Day: Revolutionising clinical trial enrolment and retention with technology
As we mark Rare Disease Day 2026, it is worth reflecting on the developments in digitalisation, artificial intelligence (AI), and …
-
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial
AtaiBeckley’s social anxiety disorder (SAD) drug has shown both safety and early signs of efficacy in a Phase IIa trial. In …
-
Bayer’s Xofigo plus Xtandi extends OS in mCRPC with bone metastases
Bayer’s radioligand therapy (RLT), Xofigo (radium-223 dichloride), has demonstrated its first-line, combinatory treatment potential in metastatic castration resistant prostate cancer …
-
Synthekine and MSD collaborate for STK-012 combination trial to treat NSCLC
Synthekine has entered a clinical trial partnership and supply agreement with Merck (MSD) to investigate STK-012 in combination with Keytruda …
-
Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new …
-
Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of …
